Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.

Bjorklund CC., Kang J., Amatangelo M., Polonskaia A., Katz M., Chiu H., Couto S., Wang M., Ren Y., Ortiz M., Towfic F., Flynt JE., Pierceall W., Thakurta A.

DOI

10.1038/s41375-019-0620-8

Type

Journal article

Journal

Leukemia

Publication Date

04/2020

Volume

34

Pages

1197 - 1201

Keywords

Adaptor Proteins, Signal Transducing, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Drug Resistance, Neoplasm, Heterocyclic Compounds, 4 or More Rings, Humans, Lenalidomide, Leukocytes, Mononuclear, Morpholines, Multiple Myeloma, Phthalimides, Piperidones, Thalidomide, Tumor Cells, Cultured, Ubiquitin-Protein Ligases

Permalink Original publication